<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is associated with reduced incretin effects </plain></SENT>
<SENT sid="1" pm="."><plain>Although previous studies have shown that <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> contributes to impaired incretin responses in beta cells, it is largely unknown how <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e>, another feature of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, contributes to impaired glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) response </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated the effects of NEFA on incretin receptor signalling and examined the <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering efficacy of incretin-based drugs in combination with the <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering agent <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used db/db mice to examine the in vivo efficacy of the treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Beta cell lines and mouse islets were used to examine GLP-1 and <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor signalling </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="2" ids="29889">Palmitate</z:chebi> treatment decreased Glp1r expression in rodent <z:e sem="disease" ids="C0021670" disease_type="Neoplastic Process" abbrv="">insulinoma</z:e> cell lines and isolated islets </plain></SENT>
<SENT sid="6" pm="."><plain>This was associated with impairment of the following: GLP-1-stimulated cAMP production, phosphorylation of cAMP-responsive elements binding protein (CREB) and insulin secretion </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:e sem="disease" ids="C0021670" disease_type="Neoplastic Process" abbrv="">insulinoma</z:e> cell lines, the expression of exogenous Glp1r restored cAMP production and the phosphorylation of CREB </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> in combination with des-fluoro-<z:chebi fb="0" ids="40237">sitagliptin</z:chebi> or exendin-4 led to more robust glycaemic control, associated with improved islet <z:mp ids='MP_0000002'>morphology</z:mp> and beta cell mass in db/db mice </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: Elevated NEFA contributes to impaired responsiveness to GLP-1, partially through downregulation of GLP-1 receptor signalling </plain></SENT>
<SENT sid="10" pm="."><plain>Improvements in <z:chebi fb="23" ids="18059">lipid</z:chebi> control in mouse models of <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> increase the efficacy of incretin-based therapy </plain></SENT>
</text></document>